中国再生医学に関するコメント

China Regenerative Medicine International's low P/S ratio may be due to its disappointing revenue performance and the expectation of this trend continuing. Its revenue growth falls short of the industry's one-year growth forecast of 79%, which may explain its lower P/S ratio compared to industry peers. The low P/S ratio could continue to impact the share price unless medium-term conditions improve.

China Regenerative Medicine International's disappointing revenue performance and discouraging growth rates suggest a continuation of its current struggle. Expected industry growth of 82% over the next year outpaces the company's projections.